Ankita Tandon (@Atandondoc) profile picture

Ankita Tandon

@Atandondoc

Medical oncology @Denver health; @University of Colorado; former chief fellow at Loyolaonc, interests #ICI #solid tumors ; views my own

 Denver, CO
Joined January 2020
  • Tweets38
  • Following153
  • Followers108
8Media
Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)Photo by Ankita Tandon (@Atandondoc)
Can’t believe this news. I had an opportunity to meet her as a first year fellow during an ASCO women in cancer mentoring session. Her passion, generosity, and enthusiasm were truly palpable. Impact she had on many lives is truly inspiring. 💔
The ASCO Post (@ASCOPost) profile pictureThe ASCO Post@ASCOPostOct 14
The oncology community mourns the passing of Rachna T. Shroff, MD, MS, FASCO, a leader in gastrointestinal cancer research, dedicated ASCO volunteer, and passionate advocate for patients and future oncologists. Learn more about her legacy ➡️ ascopost.com/news/october-20…
Image from The ASCO Post (@ASCOPost)
1
75
Check out our article especially for graduating fellows. @ASCOTECAG @HemOncFellows Negotiating Your First Contract for Your Oncology Career: Strategies to Employ and Pitfalls to Avoid | ASCO Connection connection.asco.org/do/negot…
Negotiating Your First Contract for Your Oncology Career: Strategies to Employ and Pitfalls to Avoid

Negotiating Your First Contract for Your Oncology Career: Strategies to Employ and Pitfalls to Avoid

Drs. Neal Bhutiani and Ankita Tandon provide a framework for approaching the first contract negotiation, making it less intimidating and boosting confidence for those working through the process.

connection.asco.org
1
1
331
Losing our Hem/Onc PD, mentor, exceptional teacher, and a friend is an irreplaceable loss. Grateful for the privilege of having trained under you. Dr. Asha Dhanarajan, you were an inspiration, leaving an impact on so many lives. It's hard to grasp that you're really gone.
Image from Ankita Tandon (@Atandondoc)
Image from Ankita Tandon (@Atandondoc)
2
425
I recently participated in the Women in Cancer Immunotherapy (WIN) workshop hosted by @sitcancer. It was an inspiring experience where I learnt from some incredible women leaders in the field. The Invaluable insights I gain will impact my career path. Thank you @sitcancer
1
4
664
After a long road to become a medical oncologist, I'm ready for next step and continue to work against cancer Thank you to everyone who helped me along the way #Gratitude #LastGraduation #Grade27✔️
5
400
What a terrific #ASCO24! I learned so much and was proud to be part of a community striving to improve our field. A shout-out to our trainee lounge and the amazing networking opportunities!
Image from Ankita Tandon (@Atandondoc)
1
2
292
Ankita Tandon retweeted
Elad Sharon (@EladSharonMD) profile picture
Elad Sharon@EladSharonMD16 Mar 2023
Honored to have been part of this team! We can’t just assume that when we say “resistant to immunotherapy” we are all saying the same thing. Congrats to @sitcancer for convening this group of experts! Together we will conquer cancer! @ASCO @ACS_Research @theNCI @jitcancer
Journal for ImmunoTherapy of Cancer (@jitcancer) profile pictureJournal for ImmunoTherapy of Cancer
@jitcancer15 Mar 2023
New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors bit.ly/3LFUwJt @JustinGainor @OmidHamidMD @MichaelEHurwitz @RZappasodi @HTawbi_MD @EladSharonMD
Image from Journal for ImmunoTherapy of Cancer (@jitcancer)
1
8
31
6,323
Ki-67 Is a Controversial Prognostic Biomarker in Early-Stage Breast Cancer. Here’s Why. dailynews.ascopubs.org/do/ki… Thanks to Dr.Lo and Dr.Su Mon for guidance @LoyolaOnc @ASCOPost – at Oak Park, IL
Ki-67 Is a Controversial Prognostic Biomarker in Early-Stage Breast Cancer. Here’s Why.

Ki-67 Is a Controversial Prognostic Biomarker in Early-Stage Breast Cancer. Here’s Why.

Adjuvant treatment with antiestrogen therapy positive/negative ovarian suppression is the cornerstone treatment of early-stage hormone receptor–positive, HER2-negative breast cancer.

dailynews.ascopubs.org
2
1
7
1,288
Team is here! All excited #ASH22 @LoyolaOnc – at New Orleans, LA
Image from Ankita Tandon (@Atandondoc)
6
ASH 22 cannot get more optic #ASH22 – at New Orleans, LA
1
5
Thank you to @FDAOncology and @ASCO for such a great workshop focused on learning about trial regulations. Was amazing to see twitter icons in person and learn from them @realrickpazdur @tmprowell @drjennifergao
Image from Ankita Tandon (@Atandondoc)
1
9
Loyola crew #ISA_2022 #Heidelberg @maria_picken @LoyolaOnc @loyolapathology
Image from Ankita Tandon (@Atandondoc)
1
1
5
Ankita Tandon retweeted
Shanu Gupta (@shanumeister) profile picture
Shanu Gupta@shanumeister6 Jun 2022
@AshleyEveEisner @SonyaBhaskarMD @Atandondoc @MinalAhson …to name a few more 👏🏽🔥🪄
2
5
Just learned what ASCO is all about Destiny-004 trial standing 👏 for long time. Love learning and meeting wonderful people #ASCO2022
Image from Ankita Tandon (@Atandondoc)
3
Love working with my @LoyolaOnc family! #hemepath #colleagues @HemOncFellows @HemeReports @HemeHouse @PathElective @LoyolaHemePath
Glenda Delgado Ramos, MD (@GlendaDelgadoR) profile pictureGlenda Delgado Ramos, MD@GlendaDelgadoR14 Mar 2022
We survived #hemepathjeopardy with this wonderful teacher @KMirza @LoyolaOnc
Image from Glenda Delgado Ramos, MD (@GlendaDelgadoR)
Image from Glenda Delgado Ramos, MD (@GlendaDelgadoR)
2
5
This study was a labor of love from residency, but we learned a lot from our mentor Dr. Hany Elmariah @MoffittNews @MoffittResearch and hope to add to the discussion about GVHD prophylaxis and management of complications. @Atandondoc @DrAmbuj sciencedirect.com/science/ar…
1
3
10
Ankita Tandon retweeted
Ilana Schlam (@IlanaSchlam) profile picture
Ilana Schlam@IlanaSchlam27 Jan 2022
After several months of scribbling these for the fellows and residents on the back of patient lists and notes, I decided to make a nicer version -Plus: does not require to understand my handwriting when reviewing #bcsm or writing notes- to share with them and @Medtwitteer
Image from Ilana Schlam (@IlanaSchlam)
Image from Ilana Schlam (@IlanaSchlam)
Image from Ilana Schlam (@IlanaSchlam)
37
188
23
693
JUST IN: Neoadjuvant nivolumab+chemo significantly improves EFS & pCR in patients w/resectable NSCLC in Phase 3 CheckMate-816 @OncoAlert @OncLive @bmsnews @DrMarkAwad @NarjustDumaMD @IASLC @JackWestMD @GlopesMd @n8pennell @neerajaiims @sands_jacob bit.ly/3kBILW7
Image from Toni Choueiri, MD (@DrChoueiri)
3
31
4
108
Starting a 12-day stint on inpatient hematology and oncology consults! Follow along in this #thread for little clinical pearls along the way. #onctwitter #hemetwitter 1/
1
3
21
In past month as a Heme/Onc fellow, I have told patients -you have stage IV disease, your disease has progressed, your disease is stable, and you have no evidence of disease. I am realizing this is not only opulence of knowledge, but also turmoil of emotions. #LearningProcess
6
Load more